At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 234 enrolled
Drug / intervention
RP5063 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
In Brief
A Phase 2 clinical trial evaluating RP5063, placebo, and 1 other intervention for Acute Schizophrenia and Schizoaffective Disorder. Completed, enrolled 234 participants across 15 sites in 5 countries.
Detailed Summary
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Schizophrenia, Schizoaffective Disorder
CountriesIndia, Malaysia, Moldova, Philippines, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedDec 2011
Primary CompletionMar 2013
TodayJul 2026
First PostedDec 12, 2011
Enrollment StartDec 1, 2011
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.6 years ago
Interventions
RP5063drug
daily
placebodrug
daily
aripiprazoledrug
daily